Fanny Chalmin
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Research Interests
Fanny Chalmin has a total of 21 co-authors. Here are the top co-authors by number of shared publications:
- Antoine Bernard
Faculté des Sciences de Santé, Université Bourgogne Franche-Comté, Dijon, France
5 shared publications - Caroline Truntzer
Université Bourgogne Europe, Centre Georges-François Leclerc, Unicancer, Cancer Biology Transfer Platform, INSERM, CTM UMR 1231, TIRECs team
5 shared publications - Christophe Hibos
University of Burgundy, Dijon, France
5 shared publications - Corentin Richard
Georges-François Leclerc Cancer Center 1 Université Bourgogne Europe UNICANCER, Unit of Molecular Biology, Department of Biology and Pathology of Cancer, ICMUB UMR CNRS 6302, Dijon, France
5 shared publications - Emeric Limagne
Université Bourgogne Europe, INSERM, Center for Translational and Molecular Medicine, Institut Agro Dijon, UMR1231, Dijon, France
5 shared publications - Etienne Humblin
Marc and Jennifer Lipschultz Precision Immunology Institute, ISMMS, NY, NY, USA
5 shared publications
Latest Publications
- 30 March 2026
- Published by Agence Bibliographique de l'Enseignement Supérieur
Rôles des cellules myéloïdes suppressives et des lymphocytes Th17 dans le cancer
Le système immunitaire joue un double rôle dans le cancer: il peut non seulement supprimer la croissance tumorale en détruisant les cellules cancéreuses, mais aussi promouvoir la progression de la tumeur en sélectionnant les cellules tumorales ou en créant un microenvironnement tumoral immunosuppresseur. Au cours de ma thèse, je me suis intéressée à deux populations du système immunitaire : les MDSC (Myeloïd Derived Suppressor Cells) et les lymphocytes Th17. Dans ce travail, nous avons exploré les mécanismes impliqués dans l’activation et dans les fonctions suppressives de ces deux populations cellulaires au cours de la croissance tumorale. Tout d’abord, nous avons montré que les cellules tumorales activaient les MDSC en libérant des exosomes exprimant HSP72 à leur surface. HSP72 à la surface des exosomes permet l’activation de STAT3 via la voie de signalisation TLR2/Myd88 dans les MDSC et favorise leur fonction suppressive. Le facteur de transcription STAT3 joue aussi un rôle fondamental dans la différenciation des lymphocytes Th17. Le rôle des lymphocytes Th17 est controversé dans la croissance tumorale. Nous avons découvert que les lymphocytes Th17 exprimaient les ectonucléotidases CD39 et CD73 soutenant ainsi leur fonction suppressive. L'expression des ectonucléotidases est dépendante de l’activation de STAT3 par l’IL-6 et de l’inhibition de Gfi-1 par le TGFβ lors de leur différenciation.
- 30 March 2026
- Published by Agence Bibliographique de l'Enseignement Supérieur
Rôles des cellules myéloïdes suppressives et des lymphocytes Th17 dans le cancer
Le système immunitaire joue un double rôle dans le cancer: il peut non seulement supprimer la croissance tumorale en détruisant les cellules cancéreuses, mais aussi promouvoir la progression de la tumeur en sélectionnant les cellules tumorales ou en créant un microenvironnement tumoral immunosuppresseur. Au cours de ma thèse, je me suis intéressée à deux populations du système immunitaire : les MDSC (Myeloïd Derived Suppressor Cells) et les lymphocytes Th17. Dans ce travail, nous avons exploré les mécanismes impliqués dans l’activation et dans les fonctions suppressives de ces deux populations cellulaires au cours de la croissance tumorale. Tout d’abord, nous avons montré que les cellules tumorales activaient les MDSC en libérant des exosomes exprimant HSP72 à leur surface. HSP72 à la surface des exosomes permet l’activation de STAT3 via la voie de signalisation TLR2/Myd88 dans les MDSC et favorise leur fonction suppressive. Le facteur de transcription STAT3 joue aussi un rôle fondamental dans la différenciation des lymphocytes Th17. Le rôle des lymphocytes Th17 est controversé dans la croissance tumorale. Nous avons découvert que les lymphocytes Th17 exprimaient les ectonucléotidases CD39 et CD73 soutenant ainsi leur fonction suppressive. L'expression des ectonucléotidases est dépendante de l’activation de STAT3 par l’IL-6 et de l’inhibition de Gfi-1 par le TGFβ lors de leur différenciation.
- Open Access
- 4 April 2023
- Published by American Association for Cancer Research (AACR)
Supplementary Figure from Hematopoietic Prostaglandin D2 Synthase Controls Tfh/Th2 Communication and Limits Tfh Antitumor Effects
Supplementary Figure from Hematopoietic Prostaglandin D2 Synthase Controls Tfh/Th2 Communication and Limits Tfh Antitumor Effects
- 4 April 2023
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Figure from Hematopoietic Prostaglandin D2 Synthase Controls Tfh/Th2 Communication and Limits Tfh Antitumor Effects
Supplementary Figure from Hematopoietic Prostaglandin D2 Synthase Controls Tfh/Th2 Communication and Limits Tfh Antitumor Effects
- Open Access
- 4 April 2023
- Published by American Association for Cancer Research (AACR)
Data from Hematopoietic Prostaglandin D2 Synthase Controls Tfh/Th2 Communication and Limits Tfh Antitumor Effects
T follicular helper (Tfh) cells are a subset of CD4+ T cells essential in immunity and have a role in helping B cells produce antibodies against pathogens. However, their role during cancer progression remains unknown. The mechanism of action of Tfh cells remains elusive because contradictory data have been reported on their protumor or antitumor responses in human and murine tumors. Like Tfh cells, Th2 cells are also involved in humoral immunity and are regularly associated with tumor progression and poor prognosis, mainly through their secretion of IL4. Here, we showed that Tfh cells expressed hematopoietic prostaglandin D2 (PGD2) synthase in a pSTAT1/pSTAT3-dependent manner. Tfh cells produced PGD2, which led to recruitment of Th2 cells via the PGD2 receptor chemoattractant receptor homologous molecule expressed on Th type 2 cells (CRTH2) and increased their effector functions. This cross-talk between Tfh and Th2 cells promoted IL4-dependent tumor growth. Correlation between Th2 cells, Tfh cells, and hematopoietic PGD2 synthase was observed in different human cancers and associated with outcome. This study provides evidence that Tfh/Th2 cross-talk through PGD2 limits the antitumor effects of Tfh cells and, therefore, could serve as a therapeutic target.
- 4 April 2023
- Published by American Association for Cancer Research (AACR)
Open AccessData from Hematopoietic Prostaglandin D2 Synthase Controls Tfh/Th2 Communication and Limits Tfh Antitumor Effects
T follicular helper (Tfh) cells are a subset of CD4+ T cells essential in immunity and have a role in helping B cells produce antibodies against pathogens. However, their role during cancer progression remains unknown. The mechanism of action of Tfh cells remains elusive because contradictory data have been reported on their protumor or antitumor responses in human and murine tumors. Like Tfh cells, Th2 cells are also involved in humoral immunity and are regularly associated with tumor progression and poor prognosis, mainly through their secretion of IL4. Here, we showed that Tfh cells expressed hematopoietic prostaglandin D2 (PGD2) synthase in a pSTAT1/pSTAT3-dependent manner. Tfh cells produced PGD2, which led to recruitment of Th2 cells via the PGD2 receptor chemoattractant receptor homologous molecule expressed on Th type 2 cells (CRTH2) and increased their effector functions. This cross-talk between Tfh and Th2 cells promoted IL4-dependent tumor growth. Correlation between Th2 cells, Tfh cells, and hematopoietic PGD2 synthase was observed in different human cancers and associated with outcome. This study provides evidence that Tfh/Th2 cross-talk through PGD2 limits the antitumor effects of Tfh cells and, therefore, could serve as a therapeutic target.
- Open Access
- 4 April 2023
- Published by American Association for Cancer Research (AACR)
Data from Hematopoietic Prostaglandin D2 Synthase Controls Tfh/Th2 Communication and Limits Tfh Antitumor Effects
T follicular helper (Tfh) cells are a subset of CD4+ T cells essential in immunity and have a role in helping B cells produce antibodies against pathogens. However, their role during cancer progression remains unknown. The mechanism of action of Tfh cells remains elusive because contradictory data have been reported on their protumor or antitumor responses in human and murine tumors. Like Tfh cells, Th2 cells are also involved in humoral immunity and are regularly associated with tumor progression and poor prognosis, mainly through their secretion of IL4. Here, we showed that Tfh cells expressed hematopoietic prostaglandin D2 (PGD2) synthase in a pSTAT1/pSTAT3-dependent manner. Tfh cells produced PGD2, which led to recruitment of Th2 cells via the PGD2 receptor chemoattractant receptor homologous molecule expressed on Th type 2 cells (CRTH2) and increased their effector functions. This cross-talk between Tfh and Th2 cells promoted IL4-dependent tumor growth. Correlation between Th2 cells, Tfh cells, and hematopoietic PGD2 synthase was observed in different human cancers and associated with outcome. This study provides evidence that Tfh/Th2 cross-talk through PGD2 limits the antitumor effects of Tfh cells and, therefore, could serve as a therapeutic target.
- 4 April 2023
- Published by American Association for Cancer Research (AACR)
Open AccessData from Hematopoietic Prostaglandin D2 Synthase Controls Tfh/Th2 Communication and Limits Tfh Antitumor Effects
T follicular helper (Tfh) cells are a subset of CD4+ T cells essential in immunity and have a role in helping B cells produce antibodies against pathogens. However, their role during cancer progression remains unknown. The mechanism of action of Tfh cells remains elusive because contradictory data have been reported on their protumor or antitumor responses in human and murine tumors. Like Tfh cells, Th2 cells are also involved in humoral immunity and are regularly associated with tumor progression and poor prognosis, mainly through their secretion of IL4. Here, we showed that Tfh cells expressed hematopoietic prostaglandin D2 (PGD2) synthase in a pSTAT1/pSTAT3-dependent manner. Tfh cells produced PGD2, which led to recruitment of Th2 cells via the PGD2 receptor chemoattractant receptor homologous molecule expressed on Th type 2 cells (CRTH2) and increased their effector functions. This cross-talk between Tfh and Th2 cells promoted IL4-dependent tumor growth. Correlation between Th2 cells, Tfh cells, and hematopoietic PGD2 synthase was observed in different human cancers and associated with outcome. This study provides evidence that Tfh/Th2 cross-talk through PGD2 limits the antitumor effects of Tfh cells and, therefore, could serve as a therapeutic target.
- 25 May 2022
- Published by American Association for Cancer Research (AACR) in Cancer Immunology Research
- Vol. 10 (7) , 900-916
Hematopoietic Prostaglandin D2 Synthase Controls Tfh/Th2 Communication and Limits Tfh Antitumor Effects
T follicular helper (Tfh) cells are a subset of CD4+ T cells essential in immunity and have a role in helping B cells produce antibodies against pathogens. However, their role during cancer progression remains unknown. The mechanism of action of Tfh cells remains elusive because contradictory data have been reported on their protumor or antitumor responses in human and murine tumors. Like Tfh cells, Th2 cells are also involved in humoral immunity and are regularly associated with tumor progression and poor prognosis, mainly through their secretion of IL4. Here, we showed that Tfh cells expressed hematopoietic prostaglandin D2 (PGD2) synthase in a pSTAT1/pSTAT3-dependent manner. Tfh cells produced PGD2, which led to recruitment of Th2 cells via the PGD2 receptor chemoattractant receptor homologous molecule expressed on Th type 2 cells (CRTH2) and increased their effector functions. This cross-talk between Tfh and Th2 cells promoted IL4-dependent tumor growth. Correlation between Th2 cells, Tfh cells, and hematopoietic PGD2 synthase was observed in different human cancers and associated with outcome. This study provides evidence that Tfh/Th2 cross-talk through PGD2 limits the antitumor effects of Tfh cells and, therefore, could serve as a therapeutic target.
- 25 May 2022
- Published by American Association for Cancer Research (AACR) in Cancer Immunology Research
- Vol. 10 (7) , 900-916
Hematopoietic Prostaglandin D2 Synthase Controls Tfh/Th2 Communication and Limits Tfh Antitumor Effects
T follicular helper (Tfh) cells are a subset of CD4+ T cells essential in immunity and have a role in helping B cells produce antibodies against pathogens. However, their role during cancer progression remains unknown. The mechanism of action of Tfh cells remains elusive because contradictory data have been reported on their protumor or antitumor responses in human and murine tumors. Like Tfh cells, Th2 cells are also involved in humoral immunity and are regularly associated with tumor progression and poor prognosis, mainly through their secretion of IL4. Here, we showed that Tfh cells expressed hematopoietic prostaglandin D2 (PGD2) synthase in a pSTAT1/pSTAT3-dependent manner. Tfh cells produced PGD2, which led to recruitment of Th2 cells via the PGD2 receptor chemoattractant receptor homologous molecule expressed on Th type 2 cells (CRTH2) and increased their effector functions. This cross-talk between Tfh and Th2 cells promoted IL4-dependent tumor growth. Correlation between Th2 cells, Tfh cells, and hematopoietic PGD2 synthase was observed in different human cancers and associated with outcome. This study provides evidence that Tfh/Th2 cross-talk through PGD2 limits the antitumor effects of Tfh cells and, therefore, could serve as a therapeutic target.